Gewinn- und Verlust: Viking Therapeutics, Inc.

Viking Therapeutics is positioned favorably in the oral GLP-1 obesity drug race, with strong Phase 2 results for VK2735. VKTX's oral candidate achieved 12.2% weight loss at the highest dose in 13 weeks, matching or exceeding peers' metrics and showing potential for further improvement. Management will focus Phase 3 dosing on 20-75 mg, balancing efficacy and tolerability while the injectable 78-week Phase 3 Vanquish trial is underway.

Viking Therapeutics has important catalysts on the horizon. Zoetis looks well-positioned to overcome recent challenges.

Revelation Biosciences (NASDAQ: REVB - Get Free Report) and Viking Therapeutics (NASDAQ: VKTX - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability. Risk and Volatility Revelation Biosciences has a beta

In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $35.32, marking a -3.13% move from the previous day.

VKTX remains a Buy for its cheap FY2030 EV/Sales valuations of 2.28x, the strong clinical trial results exceeding legacy players, and the potential GLP-1 monetization upon US FDA approval. The management has also prudently focused on the oral/subcutaneous VK2735 clinical trials, potentially stretching their balance sheet over the next two years of unprofitability before requiring any capital raises. Execution risks persist, due to VKTX's Phase 3 trial completion no earlier than 2027 and commercialization sometime in 2028, along with future dilution risks from negative cash flows.

In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $36.41, marking a +2.85% move from the previous day.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Viking Therapeutics, Inc. (NASDAQ: VKTX - Get Free Report) has received a consensus rating of "Moderate Buy" from the sixteen ratings firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation, nine have assigned a buy recommendation and three have

A $1,000 investment can be an ideal amount to invest in an up-and-coming growth stock. The stocks below are still modest in size, with market capitalization of less than $6 billion.

Takeover activity has been high lately in the intensely competitive anti-obesity drug space. Viking's pipeline may contain plenty of hidden value that a larger company might release.